Literature DB >> 17361343

Muscarinic acetylcholine receptor status in Alzheimer's disease assessed using (R, R) 123I-QNB SPECT.

Sanjeet Pakrasi1, Sean J Colloby, Michael J Firbank, Elaine K Perry, David J Wyper, Jonathan Owens, Ian G McKeith, E David Williams, John T O'Brien.   

Abstract

BACKGROUND: One of the most characteristic changes in Alzheimer's disease (AD) is a deficit in cortical cholinergic neurotransmission and associated receptor changes.
OBJECTIVE: To investigate differences in the distribution of M1/M4 receptors using (R, R) (123)I-iodo-quinuclidinyl-benzilate (QNB) and single photon emission computed tomography (SPECT) in patients with mild/moderate AD and age-matched controls. Also, to compare (123)I-QNB uptake to the corresponding changes in regional cerebral blood flow (rCBF) in the same subjects.
METHODS: Forty two subjects (18 AD and 24 healthy elderly controls) underwent (123)IQNB and perfusion (99m)Tc-exametazime SPECT scanning. Image analysis was performed using statistical parametric mapping (SPM99) following intensity normalisation of each image to its corresponding mean whole brain uptake. Group differences and correlations were assessed using two sample t-tests and linear regression respectively.
RESULTS: Significant reductions in (123)I-QNB uptake were observed in regions of the frontal rectal gyrus, right parahippocampal gyrus, left hippocampus and areas of the left temporal lobe in AD compared to controls (height threshold of p < or = 0.001 uncorrected). Such regions were also associated with marked deficits in rCBF. No significant correlations were identified between imaging data and clinical variables.
CONCLUSION: Functional impairment as measured by rCBF is more widespread than changes in M1/M4 receptor density in mild/moderate AD, where there was little or no selective loss of M1/M4 receptors in these patients that was greater than the general functional deficits shown on rCBF scans.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17361343     DOI: 10.1007/s00415-006-0473-8

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  35 in total

1.  Selective loss of central cholinergic neurons in Alzheimer's disease.

Authors:  P Davies; A J Maloney
Journal:  Lancet       Date:  1976-12-25       Impact factor: 79.321

2.  Systematic regional variations in the loss of cortical cholinergic fibers in Alzheimer's disease.

Authors:  C Geula; M M Mesulam
Journal:  Cereb Cortex       Date:  1996 Mar-Apr       Impact factor: 5.357

3.  Language comprehension and regional cerebral defects in frontotemporal degeneration and Alzheimer's disease.

Authors:  M Grossman; F Payer; K Onishi; M D'Esposito; D Morrison; A Sadek; A Alavi
Journal:  Neurology       Date:  1998-01       Impact factor: 9.910

4.  An improved method for rapid and efficient radioiodination of iodine-123-IQNB.

Authors:  K S Lee; X S He; D W Jones; R Coppola; J G Gorey; M B Knable; B R deCosta; K C Rice; D R Weinberger
Journal:  J Nucl Med       Date:  1996-12       Impact factor: 10.057

5.  CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia.

Authors:  M Roth; E Tym; C Q Mountjoy; F A Huppert; H Hendrie; S Verma; R Goddard
Journal:  Br J Psychiatry       Date:  1986-12       Impact factor: 9.319

6.  The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia.

Authors:  J L Cummings; M Mega; K Gray; S Rosenberg-Thompson; D A Carusi; J Gornbein
Journal:  Neurology       Date:  1994-12       Impact factor: 9.910

7.  Acetylcholine muscarinic receptors and response to anti-cholinesterase therapy in patients with Alzheimer's disease.

Authors:  Derek Brown; Jennifer A Chisholm; Jonathan Owens; Sally Pimlott; Jim Patterson; David Wyper
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-11-26       Impact factor: 9.236

8.  Muscarinic acetylcholine receptors in Alzheimer's disease. In vivo imaging with iodine 123-labeled 3-quinuclidinyl-4-iodobenzilate and emission tomography.

Authors:  B L Holman; R E Gibson; T C Hill; W C Eckelman; M Albert; R C Reba
Journal:  JAMA       Date:  1985-12-06       Impact factor: 56.272

9.  Neocortical cholinergic neurons in elderly people.

Authors:  P White; C R Hiley; M J Goodhardt; L H Carrasco; J P Keet; I E Williams; D M Bowen
Journal:  Lancet       Date:  1977-03-26       Impact factor: 79.321

10.  Deficits in iodine-labelled 3-quinuclidinyl benzilate binding in relation to cerebral blood flow in patients with Alzheimer's disease.

Authors:  D J Wyper; D Brown; J Patterson; J Owens; R Hunter; E Teasdale; J McCulloch
Journal:  Eur J Nucl Med       Date:  1993-05
View more
  9 in total

1.  Development of a highly selective, orally bioavailable and CNS penetrant M1 agonist derived from the MLPCN probe ML071.

Authors:  Evan P Lebois; Gregory J Digby; Douglas J Sheffler; Bruce J Melancon; James C Tarr; Hyekyung P Cho; Nicole R Miller; Ryan Morrison; Thomas M Bridges; Zixiu Xiang; J Scott Daniels; Michael R Wood; P Jeffrey Conn; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2011-08-24       Impact factor: 2.823

2.  Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system.

Authors:  Evan P Lebois; Thomas M Bridges; L Michelle Lewis; Eric S Dawson; Alexander S Kane; Zixiu Xiang; Satyawan B Jadhav; Huiyong Yin; J Phillip Kennedy; Jens Meiler; Colleen M Niswender; Carrie K Jones; P Jeffrey Conn; C David Weaver; Craig W Lindsley
Journal:  ACS Chem Neurosci       Date:  2010       Impact factor: 4.418

Review 3.  The antipsychotic potential of muscarinic allosteric modulation.

Authors:  Thomas M Bridges; Evan P LeBois; Corey R Hopkins; Michael R Wood; Carrie K Jones; P Jeffrey Conn; Craig W Lindsley
Journal:  Drug News Perspect       Date:  2010-05

4.  Cortical M1 receptor concentration increases without a concomitant change in function in Alzheimer's disease.

Authors:  Cassia R Overk; Christian C Felder; Yuan Tu; Doug A Schober; Kelly R Bales; Joanne Wuu; Elliott J Mufson
Journal:  J Chem Neuroanat       Date:  2010-03-27       Impact factor: 3.052

5.  Regional covariance of muscarinic acetylcholine receptors in Alzheimer's disease using (R, R) [(123)I]-QNB SPECT.

Authors:  Sean J Colloby; Ian G McKeith; David J Wyper; John T O'Brien; John-Paul Taylor
Journal:  J Neurol       Date:  2015-06-30       Impact factor: 4.849

6.  Further exploration of M₁ allosteric agonists: subtle structural changes abolish M₁ allosteric agonism and result in pan-mAChR orthosteric antagonism.

Authors:  Douglas J Sheffler; Christian Sevel; Uyen Le; Kimberly M Lovell; James C Tarr; Sheridan J S Carrington; Hyekyung P Cho; Gregory J Digby; Colleen M Niswender; P Jeffrey Conn; Corey R Hopkins; Michael R Wood; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2012-11-09       Impact factor: 2.823

7.  Higher levels of different muscarinic receptors in the cortex and hippocampus from subjects with Alzheimer's disease.

Authors:  Elizabeth Scarr; Catriona McLean; Brian Dean
Journal:  J Neural Transm (Vienna)       Date:  2016-09-29       Impact factor: 3.575

8.  Cholinergic and perfusion brain networks in Parkinson disease dementia.

Authors:  Sean J Colloby; Ian G McKeith; David J Burn; David J Wyper; John T O'Brien; John-Paul Taylor
Journal:  Neurology       Date:  2016-06-15       Impact factor: 9.910

Review 9.  Drug Development in Alzheimer's Disease: The Contribution of PET and SPECT.

Authors:  Lieven D Declercq; Rik Vandenberghe; Koen Van Laere; Alfons Verbruggen; Guy Bormans
Journal:  Front Pharmacol       Date:  2016-03-31       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.